Olanzapine in Bipolar Disorder with Bradycardia

Cardiac Safety and Efficacy

Olanzapine demonstrates the least QTc interval prolongation among all antipsychotics studied, with only a 2 ms mean prolongation compared to haloperidol's 7 ms, making it the safest option for patients with pre-existing cardiac conduction abnormalities like bradycardia 1, 2
The American College of Cardiology recommends olanzapine as the preferred first-line agent for patients with prolonged QT interval or cardiac disease 2

Quetiapine can be started at 12.5 mg twice daily, with a maximum dose of 200 mg twice daily, but it is more sedating than olanzapine with risk of transient orthostasis, which may be problematic in bradycardic patients 1
Risperidone 0.5-1 mg daily can be considered, with target doses of 2 mg/day for most patients, but extrapyramidal symptoms increase significantly at doses ≥2 mg/day 1
Obtain baseline ECG before initiating any antipsychotic therapy, and check electrolytes, particularly potassium and magnesium, as deficiencies significantly increase cardiac risk 2

Thioridazine must be avoided entirely due to 25-30 ms mean QTc prolongation and FDA black box warning 2
Droperidol carries an FDA black box warning for dysrhythmias 2
Ziprasidone should be avoided despite its efficacy, as it causes variable QTc prolongation ranging from 5-22 ms 1, 2

Discontinue the antipsychotic immediately if QTc exceeds 500 ms or increases by >60 ms from baseline 2
Do not assume all atypical antipsychotics are equally safe for cardiac patients—there are significant differences in QTc prolongation 1, 3
Avoid polypharmacy with multiple QTc-prolonging medications, as the risk increases exponentially 2